Ascorbic acid kills Epstein-Barr virus positive Burkitt lymphoma cells and Epstein-Barr virus transformed B-cells in vitro, but not in vivo

Leukemia and Lymphoma

Volumn 54, Issue 5, 2013, Pages 1069-1078

  Shatzer, Amber N ^a   Espey, Michael Graham ^b   Chavez, Mayra ^a   Tu, Hongbin ^b   Levine, Mark ^b   Cohen, Jeffrey I ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Ascorbic acid; Bortezomib; Burkitt; Epstein Barr virus; Lymphoma; Reactive oxygen species

Indexed keywords

ASCORBIC ACID; BORTEZOMIB; IMMEDIATE EARLY PROTEIN BZLF1; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL DEATH; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; ENZYME SYNTHESIS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOBLASTOID CELL; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; TREATMENT DURATION; VIRUS CELL TRANSFORMATION; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASCORBIC ACID; BORONIC ACIDS; BURKITT LYMPHOMA; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, VIRAL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MICE; PYRAZINES; REACTIVE OXYGEN SPECIES; VIRUS REPLICATION;

EID: 84876245373     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.739686     Document Type: Article

References (35)

1. Keller SA, Hernandez-Hopkins D, Vider J, et al. NF-kappaB is essential for the progression of KSHV-and EBV-infected lymphomas in vivo. Blood 2006; 107: 3295-3302.
2. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-492.
3. Cohen JI, Bollard CM, Khanna R, et al. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma 2008; 49(Suppl. 1):27-34.
4. Imai S, Koizumi S, Sugiura M, et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA 1994;91:9131-9135.
5. Sugiura M, Imai S, Tokunaga M, et al. Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Br J Cancer 1996; 74: 625-631.
6. Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991;337:320-322.
7. Pathmanathan R, Prasad U, Sadler R, et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995;333:693-698.
8. Chiang AK, Tao Q, Srivastava G, et al. Nasal NK-and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 1996;68:285-290.
9. Chen CL, Sadler RH, Walling DM, et al. Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol 1993;67:6303-6308.
10. Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodefciency. Medicine (Baltimore) 1991;70:137-160.
11. MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991;338:969-973.
12. Rea D, Delecluse HJ, Hamilton-Dutoit SJ, et al. Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas. French Study Group of Pathology for HIV-associated Tumors. Ann Oncol 1994; 5(Suppl. 1): 113-116.
13. Hamilton-Dutoit SJ, Rea D, Raphael M, et al. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodef ciency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 1993;143:1072-1085.
14. Zou P, Kawada J, Pesnicak L, et al. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol 2007; 81: 10029-10036.
15. Cahir-McFarland ED, Carter K, Rosenwald A, et al. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 2004;78:4108-4119.
16. Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci USA 2004;101:4960-4965.
17. Lassoued S, Ben Ameur R, Ayadi W, et al. Epstein-Barr virus induces an oxidative stress during the early stages of infection in B lymphocytes, epithelial, and lymphoblastoid cell lines. Mol Cell Biochem 2008;313:179-186.
18. Osipova-Goldberg HI, Turchanowa LV, Adler B, et al. H2O2 inhibits BCR-dependent immediate early induction of EBV genes in Burkitt's lymphoma cells. Free Radic Biol Med 2009; 47: 1120-1129.
19. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005;102:13604-13609.
20. Chen Q, Espey MG, Sun AY, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008; 105: 11105-11109.
21. Verrax J, Calderon PB. Pharmacologic concentrationsof ascorbate are achieved by parenteral administration and exhibit antitumoral efects. Free Radic Biol Med 2009;47:32-40.
22. Ohno S, Ohno Y, Suzuki N, et al. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res 2009;29:809-815.
23. Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr 2011;2:78-88.
24. Monti DA, Mitchell E, Bazzan AJ, et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 2012;7:e29794.
25. Kawada J, Zou P, Mazitschek R, et al. Tubacin kills epstein-barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. J Biol Chem 2009;284:17102-17109.
26. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
27. Washko PW, Welch RW, Dhariwal KR, et al. Ascorbic acid and dehydroascorbic acid analyses in biological samples. Anal Biochem 1992;204:1-14.
28. Nakano A, Abe M, Oda A, et al. Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib. Int J Hematol 2011; 93: 727-735.
29. Rowe M, Young LS, Crocker J, et al. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 1991;173:147-158.
30. Feng WH, Kenney SC. Valproic acid enhances the Effcacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 2006; 66: 8762-8769.
31. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009;8:579-591.
32. Chen Q, Espey MG, Sun AY, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular f uid in vivo. Proc Natl Acad Sci USA 2007;104:8749-8754.
33. Bannerman B, Xu L, Jones M, et al. Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol 2011;68:1145-1154.
34. Perrone G, Hideshima T, Ikeda H, et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 2009;23:1679-1686.
35. Zou W, Yue P, Lin N, et al. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 2006; 12: 273-280.